Cargando…
miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at base...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708164/ https://www.ncbi.nlm.nih.gov/pubmed/34945769 http://dx.doi.org/10.3390/jpm11121297 |
_version_ | 1784622615302766592 |
---|---|
author | Vader, Maartje J. C. Habani, Yasmin I. Schlingemann, Reinier O. Klaassen, Ingeborg |
author_facet | Vader, Maartje J. C. Habani, Yasmin I. Schlingemann, Reinier O. Klaassen, Ingeborg |
author_sort | Vader, Maartje J. C. |
collection | PubMed |
description | Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at baseline from 135 patients who were included in the BRDME study, a randomized controlled comparative trial of monthly bevacizumab or ranibizumab treatment for 6 months in patients with diabetic macular edema (Trialregister.nl, NTR3247). Best corrected visual acuity letter score (BCVA) and retinal central area thickness (CAT) were measured monthly during the 6-month follow-up. Levels of selected miRNAs were quantified. Results: Following linear regression analysis, the levels of four miRNAs were negatively associated with baseline CAT. Multivariable regression analysis confirmed this association for miR-181a. No associations with changes in CAT after 3 or 6 months of anti-VEGF treatment were found. In addition, no associations with miRNA levels with baseline BCVA or change in BCVA after 3 or 6 months of anti-VEGF treatment were found. Conclusions: Circulating miR-181a levels were negatively associated with CAT at baseline. However, no associations between miRNA levels and the response to anti-VEGF therapy were found. |
format | Online Article Text |
id | pubmed-8708164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87081642021-12-25 miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema Vader, Maartje J. C. Habani, Yasmin I. Schlingemann, Reinier O. Klaassen, Ingeborg J Pers Med Article Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at baseline from 135 patients who were included in the BRDME study, a randomized controlled comparative trial of monthly bevacizumab or ranibizumab treatment for 6 months in patients with diabetic macular edema (Trialregister.nl, NTR3247). Best corrected visual acuity letter score (BCVA) and retinal central area thickness (CAT) were measured monthly during the 6-month follow-up. Levels of selected miRNAs were quantified. Results: Following linear regression analysis, the levels of four miRNAs were negatively associated with baseline CAT. Multivariable regression analysis confirmed this association for miR-181a. No associations with changes in CAT after 3 or 6 months of anti-VEGF treatment were found. In addition, no associations with miRNA levels with baseline BCVA or change in BCVA after 3 or 6 months of anti-VEGF treatment were found. Conclusions: Circulating miR-181a levels were negatively associated with CAT at baseline. However, no associations between miRNA levels and the response to anti-VEGF therapy were found. MDPI 2021-12-04 /pmc/articles/PMC8708164/ /pubmed/34945769 http://dx.doi.org/10.3390/jpm11121297 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vader, Maartje J. C. Habani, Yasmin I. Schlingemann, Reinier O. Klaassen, Ingeborg miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema |
title | miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema |
title_full | miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema |
title_fullStr | miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema |
title_full_unstemmed | miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema |
title_short | miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema |
title_sort | mirna levels as a biomarker for anti-vegf response in patients with diabetic macular edema |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708164/ https://www.ncbi.nlm.nih.gov/pubmed/34945769 http://dx.doi.org/10.3390/jpm11121297 |
work_keys_str_mv | AT vadermaartjejc mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema AT habaniyasmini mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema AT schlingemannreiniero mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema AT klaasseningeborg mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema |